Complete Up To Date Information about Cortaba Tablets.
NADA Number: 011-700 | |
| Proprietary Name |
Cortaba® Tablets |
|---|---|
| Sponsor |
Pharmacia & Upjohn Co. |
| Sponsor Address |
a Division of Pfizer, Inc. 235 East 42nd St. New York, NY 10017 USA |
| Ingredients |
Methylprednisolone Acetylsalicylic Acid |
| Species |
Dog, restricted during pregnancy |
| Routes of Administration |
Per Os |
| Dose Form |
Tablet |
| Drug Form |
Tablet |
| Dispensing Status |
RX |
|
Dosage Amount, Indications & Limitations |
520.1409 Methylprednisolone aspirin tablets. Specifications: Each tablet contains 0.5 milligram of methylprednisolone and 300 milligrams of aspirin. Conditions of use: Dogs Amount: Dogs under 15 pounds, 1/4 to 1 tablet daily; 15 to 60 pounds, 1 to 2 tablets daily; 60 pounds and over, 2 tablets daily. Indications: As an anti-inflammatory and analgesic agent in dogs. Limitations: Administer total daily dose in divided doses 6 to 10 hours apart, with a light feeding. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Do not administer to cats. Do not overdose. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with tuberculosis, chronic nephritis, peptic ulcer, or Cushingoid syndrome. The presence of diabetes mellitus, osteoporosis predisposition to thrombophlebitis, hypertension, congestive heart failure, or renal insufficiency necessitates carefully controlled use of corticosteroids. Anti-inflammatory action of corticosteroids may mask signs of infection. NAS/NRC status: The conditions of use have been NAS/NRC reviewed and found effective. New animal drug applications for approval of drugs for these conditions of use need not include effectiveness data by 514.111 of this chapter, but may require bioequivalency and safety information. |
| Tolerances |
A tolerance is established for negligible residues of methylprednisolone in milk at 10 parts per billion. |